Print  |  Close

A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®14045 in Patients With CD123-Expressing Hematologic Malignancies


Active: Yes
Cancer Type: Leukemia
Lymphoma
Myelodysplastic Syndromes (MDS)
Skin Cancer (Non-Melanoma)
NCT ID: NCT02730312
Trial Phases: Phase I Protocol IDs: XmAb14045-01 (primary)
NCI-2016-00916
Eligibility: 18 Years and older, Male and Female Study Type: Treatment
Study Sponsor: Xencor, Inc.
NCI Full Details: http://clinicaltrials.gov/show/NCT02730312

Summary

The purpose of this study is to determine the safety and tolerability of weekly intravenous (IV) administration of XmAb14045 and to determine the maximally tolerated dose (MTD) after the first dose, and then to determine the MTD after second and subsequent infusions.

Treatment Sites in Georgia

Blood and Marrow Transplant Group of Georgia
Suite 1000
5670 Peachtree Dunwoody Road, NE
Atlanta, GA 30342
www.bmtga.com/



Emory University Hospital - Atlanta
1364 Clifton Road NE
Atlanta, GA 30322
www.emoryhealthcare.org



Northside Hospital Cancer Institute
1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-303-3355
www.northside.com



Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.